Applying for a Grant
Lilly provides grants and/or charitable contributions for all of our areas of focus through the Lilly Grant Office (LGO). Our commitment is to make grant funding available for independent, fair, and balanced, scientifically accurate initiatives that receive no influence from our organization in either submission, design, or implementation. Regardless of whether continuing education credits are offered for healthcare professional participation, Lilly expects that the same high standards apply for all independent educational activities for healthcare professionals.
Lilly adheres to the Standards for Integrity and Independence in Accredited Continuing Education established by the Accreditation Council for Continuing Medical Education (ACCME™) or any applicable governing or accrediting body standards. The company also complies with the principles established by the Office of Inspector General (OIG) Compliance Guidance for Pharmaceutical Manufacturers and Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Medical Professionals.
Additionally, Lilly has entered into partnerships and alliances with other pharmaceutical companies and established grant offices to support continuing medical education for healthcare professionals in specific therapeutic areas. The application process for all our grant offices can be accessed from this page.
Lilly Grant Office
Information related to Lilly’s areas of focus, requirements (registration, application, and after approval), transparency disclosure requirements, and answers to frequently asked questions are available within this website for your consideration before application.
Who should NOT submit applications through the LGO:
- An individual
- Organizations requesting grants that do not meet the criteria outlined on this website.
- Organizations requesting grants for clinical or investigator-initiated trials.
- Organizations based in Canada, China, or Japan.
- Organizations looking for a country-specific grant outside the U.S. (i.e., the organization and target audience are all in a single country).
- Organizations found to be listed on the Office of Inspector General's List of Excluded Individuals/Entities (OIG LEIE) or the General Services Administration Excluded Parties List System (GSA EPLS).
Partners in Diabetes
Boehringer Ingelheim – Lilly Grant Office
On January 11, 2011, Boehringer Ingelheim Pharmaceutical Inc. (BIPI) and Lilly announced a global agreement to jointly develop a portfolio of diabetes compounds. We are committed to supporting education that fosters innovative, high quality, independent medical education for healthcare professionals and patients that narrows unmet medical needs, maintains clinical excellence, and measurably improves health outcomes in areas of interest to the BIPI and Lilly Diabetes Alliance.